Back to top
more

Insulet (PODD)

(Delayed Data from NSDQ)

$174.43 USD

174.43
614,615

+1.01 (0.58%)

Updated May 3, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (151 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PODD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Insulet Corporation [PODD]

Reports for Purchase

Showing records 201 - 220 ( 341 total )

Company: Insulet Corporation

Industry: Medical - Products

Record: 201

11/05/2015

Company Report

Pages: 7

Improving Business Trends Tough To Ignore This Time; Raising PT to $44; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 202

10/29/2015

Daily Note

Pages: 6

Drug Delivery and International Performing Very Well; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 203

10/29/2015

Company Report

Pages: 7

Insulin Pump Project: Historical survey of ~5,700 users, reiterate STRONG BUY

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 204

10/28/2015

Daily Note

Pages: 5

Ypsomed FY1H16 Results Suggest It Remains On Track To Grow Its OmniPod Installed Base by 40%; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 205

10/21/2015

Daily Note

Pages: 5

Neulasta On-Body Injector Symphony Health Sales Estimate: September Data Suggests A Return to Solid Share Gains; Maintain OUTPERFORM and $40 PT

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 206

10/19/2015

Daily Note

Pages: 45

3Q15 Preview: MedTech Fundamentals Remain Intact Despite Market Volatility

Provider: WEDBUSH SECURITIES INC.

Price: 100.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 207

10/19/2015

Daily Note

Pages: 45

3Q15 Preview: MedTech Fundamentals Remain Intact Despite Market Volatility

Provider: WEDBUSH SECURITIES INC.

Price: 100.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 208

09/24/2015

Daily Note

Pages: 6

Neulasta On Body Injector Symphony Health Sales Estimate

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 209

09/24/2015

Daily Note

Pages: 6

Neulasta On Body Injector Symphony Health Sales Estimate

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 210

08/20/2015

Daily Note

Pages: 5

July Neulasta Sales Suggest Impressive OBI Adoption Representing 22% of Neulasta Franchise; Positive for PODD Drug Delivery; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 211

08/20/2015

Daily Note

Pages: 5

July Neulasta Sales Suggest Impressive OBI Adoption Representing 22% of Neulasta Franchise; Positive for PODD Drug Delivery; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 212

08/13/2015

Company Report

Pages: 9

Despite Some Confusion, The Message That Things Are Improving Is Clear; Raising PT to $40; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 213

08/13/2015

Company Report

Pages: 9

Q2 - the mystery of US OmniPod sales versus patient adds; maintain HOLD

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 214

07/30/2015

Daily Note

Pages: 5

2Q Beat And Favorable Guidance Suggest PODD Is Regaining Momentum; Historical Accounting Issue Is A Minor Distraction; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 215

07/30/2015

Company Report

Pages: 9

Q2 results ahead of estimates and survey of 5,500+ pump users (2007 - present)

Provider: Feltl & Company

Analyst: HAYNOR B

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 216

07/30/2015

Daily Note

Pages: 5

Amgen Highlights Solid Launch of Neulasta On- Body Injector (OmniPod inside)

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 217

07/30/2015

Daily Note

Pages: 5

Amgen Highlights Solid Launch of Neulasta On- Body Injector (OmniPod inside)

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 218

07/30/2015

Daily Note

Pages: 5

2Q Beat And Favorable Guidance Suggest PODD Is Regaining Momentum

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 219

07/22/2015

Daily Note

Pages: 4

June Estimate Suggests On-Body Injector Represents 10% of Neulasta Sales; Positive for PODD''s Drug Delivery Business Outlook

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 220

07/22/2015

Daily Note

Pages: 4

June Estimate Suggests On-Body Injector Represents 10% of Neulasta Sales; Positive for PODD''s Drug Delivery Business Outlook

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party